[논문]COVID-19 Vaccine: Critical Questions with Complicated Answers

Haidere, Mohammad Faisal; Ratan, Zubair Ahmed; Nowroz, Senjuti; Zaman, Sojib Bin; Jung, You-Jung; Hosseinzadeh, Hassan; Cho, Jae Youl

doi:10.4062/biomolther.2020.178

[국내논문] COVID-19 Vaccine: Critical Questions with Complicated Answers 원문보기

Biomolecules & therapeutics, v.29 no.1, 2021년, pp.1 - 10

Haidere, Mohammad Faisal (Department of Soil, Water and Environment, University of Dhaka) , Ratan, Zubair Ahmed (School of Health & Society, University of Wollongong) , Nowroz, Senjuti (Department of Chemistry, University of Dhaka) , Zaman, Sojib Bin (Department of Medicine, School of Clinical Sciences, Monash University) , Jung, You-Jung (Biological Resources Utilization Department, National Institute of Biological Resources) , Hosseinzadeh, Hassan (School of Health & Society, University of Wollongong) , Cho, Jae Youl (Department of Integrative Biotechnology, and Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University)

Abstract ▼ AI-Helper

COVID-19 has caused extensive human casualties with significant economic impacts around the globe, and has imposed new challenges on health systems worldwide. Over the past decade, SARS, Ebola, and Zika also led to significant concerns among the scientific community. Interestingly, the SARS and Zika epidemics ended before vaccine development; however, the scholarly community and the pharmaceutical companies responded very quickly at that time. Similarly, when the genetic sequence of SARS-CoV-2 was revealed, global vaccine companies and scientists have stepped forward to develop a vaccine, triggering a race toward vaccine development that the whole world is relying on. Similarly, an effective and safe vaccine could play a pivotal role in eradicating COVID-19. However, few important questions regarding SARS-CoV-2 vaccine development are explored in this review.

Keyword

표/그림 (5)

그림 Fig. 1. State of the vaccine race for COVID-19.
그림 Fig. 2. COVID-19 and the vaccine. (A) A simple representation of the COVID-19 infection mechanism in the body. (B) Basic principles of vaccines in generalized form.
표 Table 1. Ongoing or planned clinical trial for COVID-19 vaccine up to 11 November 2020
표 Table 1. Continued
표 Table 2. Historical concerns about vaccine safety

AI 본문요약
AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

An efficient vaccine is the best option for controlling and prevention COV- ID-19 pandemic. Addressing the raised questions in this paper will improve the safety and efficacy of any COVID-19 vaccine.

가설 설정

Now, the question arises. Will it be possible to overcome the backfires in developing COVID-19 vaccine? In brief, researchers need to resolve these questions to develop effective and safe vaccines against COVID-19 infection. However, this is not a comprehensive list as COVID-19 infection is a dynamic phenomenon depending on a lot of factors.

참고문헌 (64)

Adams E. R. Ainsworth M. Anand R. Andersson M. I. Auckland K. Baillie J. K. Barnes E. Beer S. Bell J. I. Berry T. 2020 Antibody testing for COVID-19: a report from the national COVID scientific advisory panel Wellcome Open Res. 5 139 10.12688/wellcomeopenres.15927.1

상세보기
Andersen K. G. Rambaut A. Lipkin W. I. Holmes E. C. Garry R. F. 2020 The proximal origin of SARS-CoV-2 Nat. Med. 26 450 452 10.1038/s41591-020-0820-9 32284615

상세보기
Andrews S. M. Rowland-Jones S. 2017 Recent advances in understanding HIV evolution F1000Res 6 597 10.12688/f1000research.10876.1 28529718

상세보기
Ascherio A. Zhang S. M. Hernan M. A. Olek M. J. Coplan P. M. Brodovicz K. Walker A. M. 2001 Hepatitis B vaccination and the risk of multiple sclerosis N. Engl. J. Med. 344 327 332 10.1056/NEJM200102013440502 11172163

상세보기
Bernstein K. E. Khan Z. Giani J. F. Cao D. Y. Bernstein E. A. Shen X. Z. 2018 Angiotensin-converting enzyme in innate and adaptive immunity Nat. Rev. Nephrol. 14 325 336 10.1038/nrneph.2018.15 29578208

상세보기
Brisse M. Vrba S. M. Kirk N. Liang Y. Ly H. 2020 Emerging concepts and technologies in vaccine development Front. Immunol. 11 583077 10.3389/fimmu.2020.583077 33101309

상세보기
Callow K. Parry H. Sergeant M. Tyrrell D. 1990 The time course of the immune response to experimental coronavirus infection of man Epidemiol. Infect. 105 435 446 10.1017/S0950268800048019 2170159

상세보기
Clem A. S. 2011 Fundamentals of vaccine immunology J. Glob. Infect. Dis. 3 73 78 10.4103/0974-777X.77299 21572612

상세보기
Corman V. M. Muth D. Niemeyer D. Drosten C. 2018 Hosts and sources of endemic human coronaviruses Advances in Virus Research, Vol. 100 Elsevier 163 188 10.1016/bs.aivir.2018.01.001
Cui W. Fan Y. Wu W. Zhang F. Wang J. y. Ni A. p. 2003 Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome Clin. Infect. Dis. 37 857 859 10.1086/378587 12955652

상세보기
Du Z. Zhu F. Guo F. Yang B. Wang T. 2020 Detection of antibodies against SARS-CoV-2 in patients with COVID-19 J. Med. Virol. doi: 10.1002/jmv.25820 [Online ahead of print] 10.1002/jmv.25820 32243608

상세보기
Duffy J. Weintraub E. Vellozzi C. DeStefano F. 2014 Narcolepsy and influenza A (H1N1) pandemic 2009 vaccination in the United States Neurology 83 1823 1830 10.1212/WNL.0000000000000987 25320099

상세보기
Ewer K. Sebastian S. Spencer A. J. Gilbert S. Hill A. V. Lambe T. 2017 Chimpanzee adenoviral vectors as vaccines for outbreak pathogens Hum. Vaccin. Immunother. 13 3020 3032 10.1080/21645515.2017.1383575 29083948

상세보기
Folegatti P. M. Ewer K. J. Aley P. K. Angus B. Becker S. Belij-Rammerstorfer S. Bellamy D. Bibi S. Bittaye M. Clutterbuck E. A. Dold C. Faust S. N. Finn A. Flaxman A. L. Hallis B. Heath P. Jenkin D. Lazarus R. Makinson R. Minassian A. M. Pollock K. M. Ramasamy M. Robinson H. Snape M. Tarrant R. Voysey M. Green C. Douglas A. D. Hill A. V. S. Lambe T. Gilbert S. C. Pollard A. J. Oxford COVID Vaccine Trial Group 2020 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Lancet 396 467 478 10.1016/S0140-6736(20)31604-4 32702298

상세보기
Gaebler C. Nussenzweig M. C. 2020 All eyes on a hurdle race for a SARS-CoV-2 vaccine Nature 586 501 502 10.1038/d41586-020-02926-w 33077943

상세보기
Gerdil C. 2003 The annual production cycle for influenza vaccine Vaccine 21 1776 1779 10.1016/S0264-410X(03)00071-9 12686093

상세보기
Gopinathan U. Peacocke E. Gouglas D. Ottersen T. Røttingen J. A. 2020 R&D for emerging infectious diseases of epidemic potential: sharing risks and benefits through a new coalition Infectious Diseases in the New Millennium Springer 137 165 10.1007/978-3-030-39819-4_7
Guo Y. R. Cao Q. D. Hong Z. S. Tan Y. Y. Chen S. D. Jin H. J. Tan K. S. Wang D. Y. Yan Y. 2020 The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status Mil. Med. Res. 7 11 10.1186/s40779-020-00240-0 32169119

상세보기
Hodgson S. H. Mansatta K. Mallett G. Harris V. Emary K. R. Pollard A. J. 2020 What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30773-8 [Online ahead of print] 10.1016/S1473-3099(20)30773-8 33125914

상세보기
Hotez P. J. Corry D. B. Bottazzi M. E. 2020 COVID-19 vaccine design: the Janus face of immune enhancement Nat. Rev. Immunol. 20 347 348 10.1038/s41577-020-0323-4 32346094

상세보기
Houser K. V. Broadbent A. J. Gretebeck L. Vogel L. Lamirande E. W. Sutton T. Bock K. W. Minai M. Orandle M. Moore I. N. Subbarao K. 2017 Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody PLoS Pathog. 13 e1006565 10.1371/journal.ppat.1006565 28817732

상세보기
Huisman W. Martina B. Rimmelzwaan G. Gruters R. Osterhaus A. 2009 Vaccine-induced enhancement of viral infections Vaccine 27 505 512 10.1016/j.vaccine.2008.10.087 19022319

상세보기
Stratton K. Almario D. A. McCormick M. C. Institute of Medicine (US) Immunization Safety Review Committe 2002 Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer National Academies Press (US) Washington DC
Iskander J. Haber P. Murphy T. 2004 Suspension of rotavirus vaccine after reports of intussusception--United States, 1999 MMWR Morb. Mortal. Wkly Rep. 53 786 789 15343145
Jamilloux Y. Henry T. Belot A. Viel S. Fauter M. El Jammal T. Walzer T. Francois B. Seve P. 2020 Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Autoimmun. Rev. 102567 10.1016/j.autrev.2020.102567 32376392

상세보기
Jouan Y. Guillon A. Gonzalez L. Perez Y. Ehrmann S. Ferreira M. Daix T. Jeannet R. Francois B. Dequin P. F. Si-Tahar M. Baranek T. Paget C. 2020 Functional alteration of innate T cells in critically ill Covid-19 patients medRxiv doi: 10.1101/2020.05.03.20089300 [Online ahead of print] 10.1101/2020.05.03.20089300
Kabbani N. Olds J. L. 2020 Does COVID19 infect the brain? If so, smokers might be at a higher risk Mol. Pharmacol. 97 351 353 10.1124/molpharm.120.000014 32238438

상세보기
Keshavarzi Arshadi A. Webb J. Salem M. Cruz E. Calad-Thomson S. Ghadirian N. Collins J. Diez-Cecilia E. Kelly B. Goodarzi H. Yuan J. S. 2020 Artificial intelligence for COVID-19 drug discovery and vaccine development Front. Artif. Intell. 3 65 10.3389/frai.2020.00065

상세보기
Khailany R. A. Safdar M. Ozaslan M. 2020 Genomic characterization of a novel SARS-CoV-2 Gene Rep. 19 100682 10.1016/j.genrep.2020.100682 32300673

상세보기
Kim D. Lee J. Y. Yang J. S. Kim J. W. Kim V. N. Chang H. 2020 The architecture of SARS-CoV-2 transcriptome Cell 181 914 921.e10 10.1016/j.cell.2020.04.011 32330414

상세보기
Kim H. W. Canchola J. G. Brandt C. D. Pyles G. Chanock R. M. Jensen K. Parrott R. H. 1969 Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am. J. Epidemiol. 89 422 434 10.1093/oxfordjournals.aje.a120955 4305198

상세보기
Kimmel S. R. 2002 Vaccine adverse events: separating myth from reality Am. Fam. Physician 66 2113 2120 12484693

상세보기
Korber B. Fischer W. Gnanakaran S. G. Yoon H. Theiler J. Abfalterer W. Foley B. Giorgi E. E. Bhattacharya T. Parker M. D. Partridge D. G. Evans C. M. Freeman T. M. de Silva T. I. LaBranche C. C. Montefiori D. C. on behalf of the Sheffield COVID-19 Genomics Group 2020 Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 bioRxiv doi: 10.1016/j.cell.2020.06.043. 10.1016/j.cell.2020.06.043 32697968

상세보기
Koyama T. Weeraratne D. Snowdon J. L. Parida L. 2020 Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment Pathogens 9 324 10.3390/pathogens9050324 32357545

상세보기
Le Houezec D. 2014 Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination Immunol. Res. 60 219 225 10.1007/s12026-014-8574-4 25395338

상세보기
Le T. T. Cramer J. P. Chen R. Mayhew S. 2020 Evolution of the COVID-19 vaccine development landscape Nat. Rev. Drug Discov. 19 667 668 10.1038/d41573-020-00151-8 32887942

상세보기
Liu L. Wei Q. Lin Q. Fang J. Wang H. Kwok H. Tang H. Nishiura K. Peng J. Tan Z. Wu T. Cheung K. W. Chan K. H. Alvarez X. Qin C. Lackner A. Perlman S. Yuen K. Y. Chen Z. 2019 Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection JCI Insight 4 e123158 10.1172/jci.insight.123158 30830861

상세보기
Long Q. X. Liu B. Z. Deng H. J. Wu G. C. Deng K. Chen Y. K. Liao P. Qiu J. F. Lin Y. Cai X. F. Wang D. Q. Hu Y. Ren J. H. Tang N. Xu Y. Y. Yu L. H. Mo Z. Gong F. Zhang X. L. Tian W. G. Hu L. Zhang X. X. Xiang J. L. Du H. X. Liu H. W. Lang C. H. Luo X. H. Wu S. B. Cui X. P. Zhou Z. Zhu M. M. Wang J. Xue C. J. Li X. F. Wang L. Li Z. J. Wang K. Niu C. C. Yang Q. J. Tang X. J. Zhang Y. Liu X. M. Li J. J. Zhang D. C. Zhang F. Liu P. Yuan J. Li Q. Hu J. L. Chen J. Huang A. L. 2020a Antibody responses to SARS-CoV-2 in patients with COVID-19 Nat. Med. 26 845 848 10.1038/s41591-020-0897-1 32350462

상세보기
Long Q. X. Tang X. J. Shi Q. L. Li Q. Deng H. J. Yuan J. Hu J. L. Xu W. Zhang Y. Lv F. J. Su K. Zhang F. Gong J. Wu B. Liu X. M. Li J. J. Qiu J. F. Chen J. Huang A. L. 2020b Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Nat. Med. 26 1200 1204 10.1038/s41591-020-0965-6 32555424

상세보기
Morris S. J. Sebastian S. Spencer A. J. Gilbert S. C. 2016 Simian adenoviruses as vaccine vectors Fut. Virol. 11 649 659 10.2217/fvl-2016-0070 29527232

상세보기
Moser M. Leo O. 2010 Key concepts in immunology Vaccine 28 C2 C13 10.1016/j.vaccine.2010.07.022 20713253

상세보기
Mullard A. 2020 COVID-19 vaccine development pipeline gears up Lancet 395 1751 1752 10.1016/S0140-6736(20)31252-6 32505245

상세보기
Naismith R. T. Cross A. H. 2004 Does the hepatitis B vaccine cause multiple sclerosis? Neurology 63 772 773 10.1212/01.WNL.0000137887.24504.30 15365121

상세보기
Offit P. A. 2005 The Cutter incident, 50 years later N. Engl. J. Med. 352 1411 1412 10.1056/NEJMp048180 15814877

상세보기
Partinen M. Saarenpaa-Heikkila O. Ilveskoski I. Hublin C. Linna M. Olsen P. Nokelainen P. Alen R. Wallden T. Espo M. Rusanen H. Olme J. Satila H. Arikka H. Kaipainen P. Julkunen I. Kirjavainen T. 2012 Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland PLoS ONE 7 e33723 10.1371/journal.pone.0033723 22470463

상세보기
Peeri N. C. Shrestha N. Rahman M. S. Zaki R. Tan Z. Bibi S. Baghbanzadeh M. Aghamohammadi N. Zhang W. Haque U. 2020 The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int. J. Epidemiol. 49 717 726 10.1093/ije/dyaa033 32086938

상세보기
Phan T. 2020 Genetic diversity and evolution of SARS-CoV-2 Infect. Genet. Evol. 81 104260 10.1016/j.meegid.2020.104260 32092483

상세보기
Ratan Z. A. Hosseinzadeh H. Runa N. J. Uddin B. M. M. Haidere M. F. Sarker S. K. Zaman S. B. 2020 Novel Coronavirus: a new challenge for medical scientist? Bangladesh J. Infect. Dis. 7 S58 S60 10.3329/bjid.v7i0.46805
Robbiani D. F. Gaebler C. Muecksch F. Lorenzi J. C. C. Wang Z. Cho A. Agudelo M. Barnes C. O. Gazumyan A. Finkin S. Hagglof T. Oliveira T. Y. Viant C. Hurley A. Hoffmann H. H. Millard K. G. Kost R. G. Cipolla M. Gordon K. Bianchini F. Chen S. T. Ramos V. Patel R. Dizon J. Shimeliovich I. Mendoza P. Hartweger H. Nogueira L. Pack M. Horowitz J. Schmidt F. Weisblum Y. Michailidis E. Ashbrook A. W. Waltari E. Pak J. E. Huey-Tubman K. E. Koranda N. Hoffman P. R. West A. P. Jr. Rice C. M. Hatziioannou T. Bjorkman P. J. Bieniasz P. D. Caskey M. Nussenzweig M. C. 2020 Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals bioRxiv doi: 10.1101/2020.05.13.092619. 10.1101/2020.05.13.092619 32511384
Santos R. A. Ferreira A. J. Simoes E Silva A. C. 2008 Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis Exp. Physiol. 93 519 527 10.1113/expphysiol.2008.042002 18310257

상세보기
Schonberger L. B. Bregman D. J. Sullivan-Bolyai J. Z. Keenlyside R. A. Ziegler D. W. Retailliau H. F. Eddins D. L. Bryan J. A. 1979 Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976-1977 Am. J. Epidemiol. 110 105 123 10.1093/oxfordjournals.aje.a112795 463869

상세보기
Shereen M. A. Khan S. Kazmi A. Bashir N. Siddique R. 2020 COVID-19 infection: origin, transmission, and characteristics of human coronaviruses J. Adv. Res. 24 91 98 10.1016/j.jare.2020.03.005 32257431

상세보기
Tetro J. A. 2020 Is COVID-19 receiving ADE from other coronaviruses? Microbes Inf. 22 72 73 10.1016/j.micinf.2020.02.006 32092539

상세보기
van Riel D. de Wit E. 2020 Next-generation vaccine platforms for COVID-19 Nat. Mater. 19 810 812 10.1038/s41563-020-0746-0 32704139

상세보기
Vickers C. Hales P. Kaushik V. Dick L. Gavin J. Tang J. Godbout K. Parsons T. Baronas E. Hsieh F. Acton S. Patane M. Nichols A. Tummino P. 2002 Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase J. Biol. Chem. 277 14838 14843 10.1074/jbc.M200581200 11815627

상세보기
Weingartl H. Czub M. Czub S. Neufeld J. Marszal P. Gren J. Smith G. Jones S. Proulx R Deschambault Y. Grudeski E. Andonov A. He R. Li Y. Copps J. Grolla A. Dick D. Berry J. Ganske S. Manning L. Cao J. 2004 Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets J. Virol. 78 12672 12676 10.1128/JVI.78.22.12672-12676.2004 15507655

상세보기
Wilder-Smith A. 2020 Dengue vaccine development: status and future Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63 40 44 10.1007/s00103-019-03060-3 31784763

상세보기
World Health Organization 2020 Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update Coronavirus Disease (COVID-19) Situation Reports, Vol. 2020 World Health Organization: WHO
Xiao A. T. Gao C. Zhang S. 2020 Profile of specific antibodies to SARS-CoV-2: the first report J. Infect. 81 147 178 10.1016/j.jinf.2020.03.012 32209385

상세보기
Yazdanpanah F. Hamblin M. R. Rezaei N. 2020 The immune system and COVID-19: friend or foe? Life Sci. 256 117900 10.1016/j.lfs.2020.117900 32502542

상세보기
Zepp F. 2010 Principles of vaccine design-lessons from nature Vaccine 28 C14 C24 10.1016/j.vaccine.2010.07.020 20713252

상세보기
Zhang C. Zhao Y. X. Zhang Y. H. Zhu L. Deng B. P. Zhou Z. L. Li S. Y. Lu X. T. Song L. L. Lei X. M. Tang W. B. Wang N. Pan C. M. Song H. D. Liu C. X. Dong B. Zhang Y. Cao Y. 2010 Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells Proc. Natil. Acad. Sci. U.S.A. 107 15886 15891 10.1073/pnas.1001253107 20798044

상세보기
Zhou Z. Ren L. Zhang L. Zhong J. Xiao Y. Jia Z. Guo L. Yang J. Wang C. Jiang S. Yang D. Zhang G. Li H. Chen F. Xu Y. Chen M. Gao Z. Yang J. Dong J. Liu B. Zhang X. Wang W. He K. Jin Q. Li M. Wang J. 2020 Heightened innate immune responses in the respiratory tract of COVID-19 patients Cell Host Microbe 27 883 890.e2 10.1016/j.chom.2020.04.017 32407669

상세보기
Zhu N. Zhang D. Wang W. Li X. Yang B. Song J. Zhao X. Huang B. Shi W. Lu R. Niu P. Zhan F. Ma X. Wang D. Xu W. Wu G. Gao G. F. Tan W. China Novel Coronavirus Investigating and Research Team 2020 A novel coronavirus from patients with pneumonia in China, 2019 N. Engl. J. Med. 382 727 733 10.1056/NEJMoa2001017 31978945

상세보기

LOADING...

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증